 Checkmate Pharmaceuticals, Inc. is a small clinical-stage biotech focused on the immune-system-based therapeutic development for combating cancer, particularly targeting TLR9 of pDCs with virus-like delivery. Checkmate Pharmaceuticals currently has one therapeutic in their pipeline known as Vidutolimod CMP-001, a CPG-A TLR9 agonist, being tested in multiple clinical trials for various indications including HNSCC and Melanoma. 